Next Generation Drug Conjugates Market

The report "Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035" is projected to reach USD 42.55 billion by 2035 from USD 15.75 billion in 2026, at a CAGR of 11.7% during the forecast period.

Browse 260 market data Tables and 60 Figures spread through 270 Pages and in-depth TOC on "Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/next-generation-drug-conjugates-ndcs-market-264674115.html

The global next generation drug conjugates market is experiencing growth, driven by increasing clinical success and Technological advancements in linker chemistry and payload development.

The Enhertu segment accounted for the largest share of the global next generation drug conjugates market, by product, in 2025.

Based on product, the next generation drug conjugates market is segmented into Enhertu, Amvuttra, Pluvicto, Trodelvy, Sacituzumab Tirumotecan (SAC-TMT), Zilebesiran, 225Ac-PSMA-617, other commercialized products, and other pipeline products. The Enhertu dominated the market share in 2025, driven by its superior clinical efficacy, strong global adoption, and expanding approvals across multiple HER2-targeted indications, particularly in breast cancer. Its growing use in HER2-low populations and ongoing clinical trials in lung and gastric cancers further support its market leadership. Additionally, the increasing prevalence of breast cancer and the rising demand for targeted therapies continue to boost the uptake of Enhertu, reinforcing its dominant position in the global NGDC market.

Amino sugar is estimated to be the fastest-growing target ligand segment.

The global next generation drug conjugates market is segmented by target ligand into antibodies, amino sugars, peptides, and other targeting ligands. In 2025, the amino sugar segment is projected to be the fastest-growing during the forecast period, driven by its emerging role in targeted delivery and improved cellular uptake. Amino sugar-based ligands offer enhanced biocompatibility and potential for selective binding, supporting their increasing adoption in novel drug conjugate development and expanding research applications in precision oncology.

North America accounted for the largest regional share in the global next generation drug conjugates market in 2025.

North America accounted for the largest share of regional revenues in the next generation drug conjugates (NGDC) market and remains the primary growth engine. The region’s dominance is driven by a high concentration of leading biopharmaceutical companies, advanced research institutions, and specialized cancer centers, along with strong regulatory support from the FDA and rapid adoption of innovative targeted therapies such as antibody-drug conjugates. Robust oncology pipelines, significant NIH and private funding, and an active clinical trials landscape position the US as the key innovation hub for NGDCs, while Canada contributes steadily through expanding healthcare infrastructure, increasing cancer research initiatives, and growing adoption of advanced oncology treatments.

Key players in the next generation drug conjugates market include Alnylam Pharmaceuticals, Inc (US), Gilead Sciences, Inc (Immunomedics) (US), Novartis AG (Switzerland), AstraZeneca (UK), Daiichi Sankyo, Company Limited (Japan), Ionis Pharmaceuticals, Inc. (US), Rakuten Group, Inc. (US), Novo Nordisk (Dicerna Pharmaceuticals) (Denmark), ADC Therapeutics SA (Switzerland), Sanofi (France), Arrowhead Pharmaceuticals (US), and AbbVie, Inc (US).

Don’t miss out on business opportunities in next generation drug conjugates market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com